Christine Kay, MD
Ophthalmology · Gainesville, FLNPI 1881898419
Payments from drug & device makers
Across 465 payments — averaging $3401.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$1M
- Biogen$277K
- Spark Therapeutics, Inc.$87K
- Novartis$54K
- Sanofi US Services Inc.$53K
- Janssen Global Services, LLC$20K
- plus $66K from 24 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 242 | $1,024,806 |
| Biogen | 10 | $276,942 |
| Spark Therapeutics, Inc. | 55 | $86,948 |
| Novartis | 2 | $53,853 |
| Sanofi US Services Inc. | 32 | $53,077 |
| Janssen Global Services, LLC | 25 | $20,224 |
| AbbVie(2 entities) | 6 | $19,754 |
| Astellas Pharma Global Development | 5 | $17,963 |
| Eyepoint US, Inc. | 2 | $11,516 |
| F. Hoffmann-la Roche AG | 1 | $3,925 |
| Cortigent Inc | 5 | $3,100 |
| Novartis Pharma AG | 1 | $2,800 |
| Johnson & Johnson | 1 | $1,815 |
| Boehringer Ingelheim International GmbH | 12 | $1,054 |
| PTC Therapeutics, Inc. | 1 | $800 |
| Alnylam Pharmaceuticals Inc. | 1 | $630 |
| Vertex | 1 | $483 |
| Regeneron Healthcare Solutions, Inc. | 14 | $418 |
| Genentech USA, Inc. | 16 | $405 |
| Astellas Pharma US Inc | 6 | $253 |
| Boston Scientific | 9 | $167 |
| Kala Pharmaceuticals, Inc. | 1 | $162 |
| Boehringer Ingelheim | 1 | $150 |
| Amgen | 1 | $123 |
| Mallinckrodt Enterprises LLC | 1 | $121 |
| Novo Nordisk | 6 | $99 |
| Apellis Pharmaceuticals, Inc. | 4 | $84 |
| Bausch & Lomb Americas Inc. | 2 | $40 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $15 |
| Halozyme Inc | 1 | $14 |
How this compares
$1,581,741 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in Gainesville
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Matthew CunninghamOrlando$2.9M
- Benjamin ThomasJacksonville$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.